465 related articles for article (PubMed ID: 25350767)
21. Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study.
Cao Z; Liu C; Xu J; You L; Wang C; Lou W; Sun B; Miao Y; Liu X; Wang X; Zhang T; Zhao Y
Oncotarget; 2016 Jul; 7(27):41575-41583. PubMed ID: 27223429
[TBL] [Abstract][Full Text] [Related]
22. Dysregulation of miRNAs Targeting the IGF-1R Pathway in Pancreatic Ductal Adenocarcinoma.
Dobre M; Herlea V; Vlăduţ C; Ciocîrlan M; Balaban VD; Constantinescu G; Diculescu M; Milanesi E
Cells; 2021 Jul; 10(8):. PubMed ID: 34440625
[TBL] [Abstract][Full Text] [Related]
23. miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma.
Tesfaye AA; Azmi AS; Philip PA
Am J Pathol; 2019 Jan; 189(1):58-70. PubMed ID: 30558723
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Prognostic Markers, Respectively.
Yu Q; Xu C; Yuan W; Wang C; Zhao P; Chen L; Ma J
Biomed Res Int; 2017; 2017():6495867. PubMed ID: 28466015
[No Abstract] [Full Text] [Related]
25. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer.
Dittmar RL; Liu S; Tai MC; Rajapakshe K; Huang Y; Longton G; DeCapite C; Hurd MW; Paris PL; Kirkwood KS; Coarfa C; Maitra A; Brand RE; Killary AM; Sen S
Cancer Prev Res (Phila); 2021 Jul; 14(7):729-740. PubMed ID: 33893071
[TBL] [Abstract][Full Text] [Related]
26. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
Nakamura K; Zhu Z; Roy S; Jun E; Han H; Munoz RM; Nishiwada S; Sharma G; Cridebring D; Zenhausern F; Kim S; Roe DJ; Darabi S; Han IW; Evans DB; Yamada S; Demeure MJ; Becerra C; Celinski SA; Borazanci E; Tsai S; Kodera Y; Park JO; Bolton JS; Wang X; Kim SC; Von Hoff D; Goel A
Gastroenterology; 2022 Nov; 163(5):1252-1266.e2. PubMed ID: 35850192
[TBL] [Abstract][Full Text] [Related]
27. Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma.
Li Q; Wang H; Zogopoulos G; Shao Q; Dong K; Lv F; Nwilati K; Gui XY; Cuggia A; Liu JL; Gao ZH
Oncotarget; 2016 Nov; 7(47):77838-77853. PubMed ID: 27788482
[TBL] [Abstract][Full Text] [Related]
28. miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells.
Zhang ZL; Bai ZH; Wang XB; Bai L; Miao F; Pei HH
PLoS One; 2015; 10(3):e0118814. PubMed ID: 25742499
[TBL] [Abstract][Full Text] [Related]
29. Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia.
Vila-Navarro E; Duran-Sanchon S; Vila-Casadesús M; Moreira L; Ginès À; Cuatrecasas M; Lozano JJ; Bujanda L; Castells A; Gironella M
Clin Transl Gastroenterol; 2019 Apr; 10(4):e00029. PubMed ID: 31009404
[TBL] [Abstract][Full Text] [Related]
30. Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer.
Ebrahimi S; Hosseini M; Ghasemi F; Shahidsales S; Maftouh M; Akbarzade H; Parizadeh SA; Hassanian SM; Avan A
Curr Pharm Des; 2016; 22(42):6444-6450. PubMed ID: 27539232
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma.
Jamieson NB; Morran DC; Morton JP; Ali A; Dickson EJ; Carter CR; Sansom OJ; Evans TR; McKay CJ; Oien KA
Clin Cancer Res; 2012 Jan; 18(2):534-45. PubMed ID: 22114136
[TBL] [Abstract][Full Text] [Related]
32. Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection.
Karasek P; Gablo N; Hlavsa J; Kiss I; Vychytilova-Faltejskova P; Hermanova M; Kala Z; Slaby O; Prochazka V
Cancer Genomics Proteomics; 2018; 15(4):321-327. PubMed ID: 29976637
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
Brunetti O; Russo A; Scarpa A; Santini D; Reni M; Bittoni A; Azzariti A; Aprile G; Delcuratolo S; Signorile M; Gnoni A; Palermo L; Lorusso V; Cascinu S; Silvestris N
Oncotarget; 2015 Sep; 6(27):23323-41. PubMed ID: 26259238
[TBL] [Abstract][Full Text] [Related]
34. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis.
Kong X; Du Y; Wang G; Gao J; Gong Y; Li L; Zhang Z; Zhu J; Jing Q; Qin Y; Li Z
Dig Dis Sci; 2011 Feb; 56(2):602-9. PubMed ID: 20614181
[TBL] [Abstract][Full Text] [Related]
35. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma.
Schultz NA; Werner J; Willenbrock H; Roslind A; Giese N; Horn T; Wøjdemann M; Johansen JS
Mod Pathol; 2012 Dec; 25(12):1609-22. PubMed ID: 22878649
[TBL] [Abstract][Full Text] [Related]
37. Shared extracellular vesicle miRNA profiles of matched ductal pancreatic adenocarcinoma organoids and blood plasma samples show the power of organoid technology.
Zeöld A; Sándor GO; Kiss A; Soós AÁ; Tölgyes T; Bursics A; Szűcs Á; Harsányi L; Kittel Á; Gézsi A; Buzás EI; Wiener Z
Cell Mol Life Sci; 2021 Mar; 78(6):3005-3020. PubMed ID: 33237353
[TBL] [Abstract][Full Text] [Related]
38. The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma.
Michael Traeger M; Rehkaemper J; Ullerich H; Steinestel K; Wardelmann E; Senninger N; Abdallah Dhayat S
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2419-2431. PubMed ID: 30244390
[TBL] [Abstract][Full Text] [Related]
39. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
[TBL] [Abstract][Full Text] [Related]
40. Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes.
Wang X; Ren H; Zhao T; Ma W; Dong J; Zhang S; Xin W; Yang S; Jia L; Hao J
Oncotarget; 2016 Mar; 7(12):13717-29. PubMed ID: 26872370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
